About ReViral
ReViral is a Healthcare company based in London (United Kingdom) founded in 2011 by Khattereh Ahmadi, and was acquired by Pfizer in April 2022. Antiviral compounds for Respiratory Syncytial Virus infections are developed. ReViral has raised $176 million across 5 funding rounds from investors including Pfizer, New Leaf Venture Partners and Orbimed. The company has 28 employees. The company was acqui-hired. ReViral offers products and services including Backorder Service and Auction Platform. Its focus areas include Life Sciences, Pulmonology, Drugs and Lung Infections. Its legal entity is REVIRAL LIMITED.
Company details
ReViral was founded in 2011 and is based in London, United Kingdom. Operations are conducted in the biotechnology sector, where antiviral compounds targeting Respiratory Syncytial Virus (RSV) are developed. The lead candidate, RV521, is progressed as a therapy for RSV infections, which frequently result in complications such as asthma, chronic obstructive pulmonary disease, or pneumonia. Focus is placed on advancing treatments for respiratory conditions.
- Headquarters London, United Kingdom
- Employees 28
- Founders Khattereh Ahmadi
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website reviral.co.uk
- Social X
- Acquired by Pfizer (Apr 2022)
- Legal Name Reviral Limited
- Date of Incorporation 10 Jan, 2011
- Jurisdiction SANDWICH, KENT, ENGLAND
Products & Services of ReViral
ReViral offers a comprehensive portfolio of products and services, including Backorder Service and Auction Platform.
Enables backordering of expiring UK domains for automatic registration.
Facilitates bidding on domains with multiple backorders.
Funding Insights of ReViral
ReViral has successfully raised a total of $176M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $44 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $176M
- Total Rounds 5
- Last Round Series C β $44M
- First Round $1M
(Dec 2014)
- Investors Count 8
All 5 funding rounds of ReViral with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $44M | Series C | β | β | |
| Aug 2018 | $55M | Series B | β | New Leaf Venture Partners, Novo Holdings | |
| Jul 2018 | $55M | Series B | β | New Leaf Venture Partners, Novo Holdings | |
| Sep 2015 | $21M | Series A | β | β | |
| Dec 2014 | $1M | Seed | β | β |
9 investors in total: 9 institutional.
Investors in ReViral
ReViral has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, New Leaf Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Brace Pharma Capital is focused on investing in innovative therapies. | bracepharma.com | Atlanta, United States | ||
Private equity investments and corporate advisory services are managed. | greensandsequity.com | San Francisco, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for ReViral
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReViral
13 people are tracked at ReViral (5 in leadership, 8 in board & advisors); the tracked headcount is 28.
| Name | Role | Group |
|---|---|---|
Khattereh Ahmadi | Co-Founder | Leadership |
Edward Littler | Executive Director | Leadership |
Alex C. Sapir | CEO | Leadership |
Eddy Littler | COO | Leadership |
Cora Griffin | Head, Business Development & Alliance Management | Leadership |
Chau Q. Khuong | Director | Board & advisors |
Lawrence Blatt | Non-Executive Director | Board & advisors |
Jason Zhou | Director | Board & advisors |
Richard N. Kender | Non-Executive Director | Board & advisors |
Ron Hunt | Director | Board & advisors |
Ken Powell | Chairman | Board & advisors |
Iain D. Dukes | Non-Executive Director | Board & advisors |
Raphaël Wisniewski | Director | Board & advisors |
Complete people profiles for ReViral
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReViral
4 dated milestones of ReViral across 11 years, from founding to its latest funding, stage changes and deals.
- Founded ReViral is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series C, of $44.0M.
- Exit Acquired by Pfizer.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as ReViral (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Reviral
Complete news archive for ReViral
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReViral
ReViral was founded in 2011 and raised its 1st funding round 3 years after it was founded.
ReViral is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
ReViral is a funded company, having raised a total of $176M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Dec 2014.
ReViral has 28 employees.
Annual revenue of ReViral is $19.68M as on Dec 31, 2016.
ReViral was founded in 2011 and is based in London, United Kingdom. Operations are conducted in the biotechnology sector, where antiviral compounds targeting Respiratory Syncytial Virus (RSV) are developed. The lead candidate, RV521, is progressed as a therapy for RSV infections, which frequently result in complications such as asthma, chronic obstructive pulmonary disease, or pneumonia. Focus is placed on advancing treatments for respiratory conditions.
ReViral offers Backorder Service and Auction Platform.
ReViral has 9 investors. Key investors include Pfizer, New Leaf Venture Partners, Orbimed, Andera Partners, and Perceptive Advisors.
ReViral operates through Reviral Limited.
Yes. ReViral was acquired by Pfizer in April 2022.

